Nevertheless, treatment with tocilizumab, an IL-6R antagonist tested in the TRANSFORM-UK phase-II trial33, did not result in significant clinical improvement in PAH patients34 in spite of one case-report showing that tocilizumab improved symptoms in a patient with PAH associated with Castleman’s disease35. Here, IL6R is linked to pulmonary arterial hypertension.